Make plans to attend this upcoming educational sessions:
Opioid Prescribing: Safe Practice, Changing Lives CME
September 17, 2016 | 12:45pm-2:45pm
Grandover Resort & Conference Center
One Thousand Club Road
Greensboro, North Carolina 27407
This session, also presented by Christopher Grubb, MD, will occur during the M3 Conference at the Grandover Resort in Greensboro, NC. The event is free for those attendees only wishing to participate in this educational session.
The treatment of pain can be a rewarding part of a medical practice, but the prescribing of opioids is fraught with numerous challenges and pitfalls. Every healthcare provider in our state is obligated to treat pain, and opioid medications are certainly useful in the treatment of moderate and severe pain. However, this mandate must be balanced by the duty to protect patients and the community at large from opiate overdoses, addiction, and the diversion of opioid medications for illicit use. Dozens of opioid pharmaceutical products are available to prescribers, and they each have unique characteristics that make them useful in treating certain types of pain; yet these same characteristics must be understood with regard to their specific impact on the risks of drug misuse and abuse. The purpose of this educational program is to improve healthcare providers’ understanding of opioids in the management of pain, including the inherent risks of abuse and misuse.
Educational goals for participants:
Learn about the opioid epidemic in our state and its relationship to opioid prescribing patterns.
Appreciate the provider’s duty to mitigate the risks of abuse, addiction, and illegal drug diversion when prescribing opioids for pain.
Review strategies for the evaluation of pain, including the assessment of opioid-related risks.
Renewed understanding of the ethical principle of “primum non nocere” (“first, do no harm”).
Review basic principles of opioid therapy for pain – acute vs. chronic pain, opioid-naïve vs. opioid-tolerant, dose selection and titration, incomplete cross-tolerance, and opioid weaning.
Learn how to properly maintain patients on chronic opioid therapy – patient agreements and consent, NC Controlled Substance Reporting System, pill counts, urine drug testing.
Understand the differences among the available extended-release and long-acting opioid products, including different delivery systems and their pharmacokinetic characteristics.
By the end of this program the healthcare providers in attendance should have a renewed motivation to treat acute and chronic pain in their respective practices. They will hopefully also leave with a desire to take a more active role in combating the drug problem in our respective communities.
The Southern Regional AHEC designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other health professionals will receive Southern Regional AHEC CEU and/or contact hours and a certificate of attendance from an AMA PRA Category 1 CreditTM activity. These certificates are accepted by the NC boards for physician assistants, nurse practitioners, and nurses. License requirements are subject to change. Southern Regional AHEC recommends that participants contact their licensing boards with specific questions. Southern Regional AHEC will provide 0.2 Continuing Education Units (2.0 contact hours) to participants upon completion of this activity.
This activity has been planned and implemented in accordance with the Essentials and Standards of the North Carolina Medical Society through the joint providership of the Southern Regional AHEC and the NCMS. The Southern Regional AHEC is accredited by the North Carolina Medical Society to provide continuing medical education for physicians.
The Southern Regional AHEC adheres to ACCME Essential Areas and Policies regarding industry support of continuing medical education. Disclosure of faculty/planning committee members and commercial relationships will be made known at the activity. Speakers are also expected to openly disclosure a discussion of any off-label, experimental, or investigational drugs or devices in their presentations.
Learn more by visiting the M3 Conference website at www.ncm3conference.com.